Pharvaris BV (US: PHVS) — Healthcare · Share Price, Chart & Market Data
About: Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $29.83 (+5.71%)
PHVSPharvaris BV
Loading watchlist status…
Trade PHVS now
Pharvaris BV share price
PHVS price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
30 Apr, 9:29 am GMT+0
PHVS price performance
4.191%
5D
9.307%
1M
12.651%
YTD
61.418%
1Y
PHVS price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
30 Apr, 9:29 am GMT+0
PHVS details
PHVS Market Signals